Rabbit Polyclonal AndrogenReceptor(Phospho-Ser213) Antibody

+ +

•  

   
     Western blot analysis of Androgen Receptor(Phospho-Ser213) expression in HEK293T (A), A549 (B), H1792 (C) whole cell lysates.    

•  

   
     Immunofluorescent analysis of Androgen Receptor(Phospho-Ser213) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.    

•  

   
     Immunohistochemical analysis of Androgen Receptor(Phospho-Ser213) staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.    

The Androgen Receptor (AR) is a ligand-activated transcription factor critical for regulating gene expression in response to androgens like testosterone and dihydrotestosterone. Post-translational modifications, including phosphorylation, tightly modulate AR activity, influencing its stability, nuclear translocation, and interactions with co-regulators. Phosphorylation at serine 213 (Ser213) is a key regulatory event linked to AR activation and signaling. This modification occurs in the N-terminal domain, a region essential for transcriptional activity, and has been implicated in both ligand-dependent and ligand-independent AR activation pathways.

The Androgen Receptor (Phospho-Ser213) antibody specifically detects AR phosphorylated at Ser213. enabling researchers to study AR activation dynamics in physiological and pathological contexts. Elevated Ser213 phosphorylation has been associated with prostate cancer progression, particularly in castration-resistant prostate cancer (CRPC), where AR signaling persists despite androgen deprivation therapy. This antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess AR activation status in cell lines, tissue samples, or preclinical models. Its applications extend to investigating AR's role in therapy resistance, identifying biomarkers for disease prognosis, and evaluating experimental therapies targeting AR or its signaling partners. By tracking Ser213 phosphorylation, this tool provides insights into AR-driven oncogenesis and potential therapeutic vulnerabilities.